The EU-European Union has announced a policy to tighten conditions on the export of vaccines manufactured in the region in response to the delay in the supply of the new coronavirus vaccine.
The EU is obliged to obtain a permit to export vaccines manufactured in the region from January, following the delay in the supply of vaccines for the new coronavirus.
On the 24th, the EU announced a policy to tighten the conditions for this export permit.
According to this,
in addition to whether the export destination country does not restrict the export of vaccines and raw materials,
▽ the infection status of that country and the progress of vaccination will be taken into consideration.
The EU is increasingly skeptical that vaccines developed by British pharmaceutical giant AstraZeneca and others may be preferentially supplied to the UK, which is believed to be the background of this time.
If this policy is officially approved, it may affect the supply of vaccines to countries outside the EU, including Japan.
At a press conference, EU Executive Vice-Chairman Dombrovskis emphasized the reason for the policy, "We need to secure a vaccine for EU citizens."
According to the EU, about 43 million vaccines have been exported to 33 countries and regions outside the region, of which about 5.4 million have been exported to Japan, the third highest.